- Home
- WHF vs KLRS Comparison
WHF vs KLRS Comparison
Compare WHF & KLRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | WHF | KLRS |
|---|---|---|
| Founded | 2011 | 2019 |
| Country | United States | United States |
| Employees | 3 | 20 |
| Industry | Finance Companies | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 164.5M | 132.8M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | WHF | KLRS |
|---|---|---|
| Price | $7.60 | $6.22 |
| Analyst Decision | Sell | Strong Buy |
| Analyst Count | 2 | 4 |
| Target Price | $7.75 | ★ $19.00 |
| AVG Volume (30 Days) | ★ 99.7K | 76.6K |
| Earning Date | 05-11-2026 | 05-13-2026 |
| Dividend Yield | ★ 13.64% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $15.35 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $6.07 | $2.14 |
| 52 Week High | $9.95 | $11.88 |
Technical Indicators
Market Signals| Indicator | WHF | KLRS |
|---|---|---|
| Relative Strength Index (RSI) | 58.41 | 43.02 |
| Support Level | $6.80 | $4.35 |
| Resistance Level | $7.62 | $7.18 |
| Average True Range (ATR) | 0.21 | 0.63 |
| MACD | 0.00 | 0.15 |
| Stochastic Oscillator | 69.86 | 51.32 |
Price Performance
Historical ComparisonAbout WHF WhiteHorse Finance Inc.
WhiteHorse Finance Inc is a non-diversified, closed-end management investment company. It makes debt investments in privately held; small-cap companies located in United States. Its investment objective is to generate risk-adjusted returns by originating and investing in senior secured loans, including first lien and second lien facilities, to performing lower middle market companies across a range of industries.
About KLRS Kalaris Therapeutics Inc.
Kalaris Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutics for prevalent retinal diseases. The company is developing TH103, a novel, clinical-stage anti-vascular endothelial growth factor VEGF drug, engineered to potentially provide longer-lasting and increased anti-VEGF activity in patients with exudative and neovascular retinal diseases. TH103 is a fully humanized recombinant fusion protein, functioning as a decoy receptor (a VEGF trap), leveraging salient molecular properties of the human body's native, highest affinity VEGF receptor 1.